Shanghai HeartCare Medical IPO: Valuation Insights
Our base-case DCF valuation is HK$186.51 per share, which is a 13% upside to the mid-point of the IPO price range of HK$160.00-171.00 per share.
741 Views
Heartcare (åæē®å»ē) IPO: Decent Upside Barring Negative Lawsuit Outcomes
We provide an update for HeartCare's book building. We think the upside is substantial barring negative outcomes from the legal proceedings with...
460 Views
Acotec (å ēč¾¾) Pre-IPO: Thoughts on Valuation
We provide our forecast and valuation for the company's two key products AcoArt Orchid & Dhalia, as well as AcoArt Tulip & Litos.
305 Views
Shanghai HeartCare (åæē®å»ē) Pre-IPO: Thoughts on Valuation
We forecast the sales of HeartCare's four key products, namely Captor, Intracranial Catheter, LAA Occluder, and embolic coil, and also provide an...
569 Views
ECM Weekly (4th July 2021) - Xpeng, Medbot, Medlive, Brii Bio, CTOS, LinkDoc, Devyani, Manycore
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
684 Views